+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates



Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates



Clinical Microbiology and Infection 16(2): 132-136



A significant inoculum-size effect has been observed with piperacillin-tazobactam, and has been associated with beta-lactamase production in extended-spectrum beta-lactamase (ESBL) producers. This association has not been previously studied in the case of amoxycillin-clavulanate. Piperacillin-tazobactam and amoxycillin-clavulanate were compared, using high inocula of susceptible strains either harbouring ESBLs or not. Two non-ESBL-producing and 15 amoxycillin-clavulanate-susceptible and piperacillin-tazobactam-susceptible ESBL-producing Escherichia coli isolates, and their respective transconjugants, were tested in dilution susceptibility tests using standard and 100-fold higher inocula. Three ESBL-producing strains and E. coli ATCC 25922 were selected for time-kill studies using standard and high initial inocula. At high inocula, MICs of piperacillin increased >eight-fold for non-ESBL-producing strains, and MICs of piperacillin-tazobactam (8:1 ratio or with tazobactam fixed at 4 mg/L) increased>eight-fold for all ESBL-producing strains. However, amoxycillin MICs were not affected by a high inoculum with non-ESBL-producing strains, whereas the MICs of amoxycillin-clavulanate (2:1 and 4:1) increased

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052210262

Download citation: RISBibTeXText

PMID: 19614715

DOI: 10.1111/j.1469-0691.2009.02893.x


Related references

Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum beta-Lactamase ESBL-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model Experimental Th. 2013

Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. ChemoTherapy 44(6): 377-384, 1998

Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrobial Agents and ChemoTherapy 57(5): 2109-2113, 2013

Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Journal of Clinical Microbiology 42(1): 269-275, 2004

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrobial Agents and ChemoTherapy 52(5): 1846-1849, 2008

Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-beta-Lactamase-Producing Escherichia coli. 2013

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 45(12): 3548-3554, 2001

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrobial Agents and ChemoTherapy 50(6): 2244-2247, 2006

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrobial Agents and ChemoTherapy 43(5): 1170-1176, 1999

Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum -Lactamase-Producing Enterobacteriaceae. Chemotherapy 44(6): 377-384, 1998

Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial Escherichia coli isolates. Mikrobiyoloji Bulteni 49(1): 15-25, 2015

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. Bmc Infectious Diseases 17(1): 404, 2017

Prevalence and Epidemiological Relationship of Cmy-2 AmpC ^|^beta;-Lactamase and Ctx-M Extended-Spectrum ^|^beta;-Lactamase-Producing Escherichia coli Isolates from Broiler Farms in Japan. Journal of Veterinary Medical Science 75(8): 1009-1015, 2013

In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli. Clinical Infectious Diseases 57(10): Iii-Iiv, 2014

Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients. Srpski Arhiv Za Celokupno Lekarstvo 141(11-12): 775-779, 2015